Ascendis Pharma A (ASND) Total Current Liabilities (2012 - 2026)

Ascendis Pharma A has reported Total Current Liabilities for 15 years, with the latest figure at $1.3 billion in Q1 2026.

• Quarterly Total Current Liabilities rose 41.62% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 41.62% YoY) and the FY2025 annual result came in at $1.2 billion, up 57.65% from the prior year.
• Total Current Liabilities rose to $1.3 billion in Q1 2026 per ASND's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $1.3 billion in Q1 2026 and troughed at $107.0 million in Q1 2022.
• A 5-year average of $658.4 million and a median of $792.4 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 353.5% in 2023, then dropped 0.36% in 2024.
• Over 5 years, Total Current Liabilities stood at $174.7 million in 2022, then jumped by 353.5% to $792.4 million in 2023, then decreased by 0.36% to $789.6 million in 2024, then surged by 57.65% to $1.2 billion in 2025, then increased by 5.97% to $1.3 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.3 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.